News

July 20, 2017July 20, 2017

New Research Data Network Aims to Advance Discovery of Huntington’s Treatment

Researchers have created the first freely available data network — called HDNetDB — that aims to advance research into Huntington’s disease and speed up drug discovery for the incurable ... Read more

July 18, 2017

Wave Life Sciences to Start Trials of Two Therapies That Target Huntington’s Mutations

News

Wave Life Sciences will start two Phase 1b/2a clinical trials to investigate the safety and tolerability of its products WVE-120101 and WVE-120102 in Huntington’s disease patients. The trials will ... Read more

July 13, 2017

People with Chorea Can Switch from Xenazine To Austedo Safely, Phase 3 Clinical Trial Shows

News

Huntington’s patients who are taking Xenazine for the twitching condition known as chorea can switch without concern to the newly approved Austedo, according to Austedo’s maker, Teva Pharmaceutical Industries. A Phase 3 ... Read more

July 11, 2017

Metabolic Changes in Certain Brain Regions May Be Associated with Huntington’s Motor Symptoms

News

A sluggish metabolism in the cells of the striatum, a brain region essential for motor function control, is associated with disease severity in Huntington’s patients, while a higher metabolism ... Read more

July 6, 2017

MSH3 Gene Mutations May Be Involved in Huntington’s Disease Progression, Study Finds

News

Mutations of the MSH3 gene may be associated with the progression of Huntington’s disease, according to a British study. The gene could become a biomarker for the disease, and ... Read more

June 29, 2017

Mitoconix Bio Obtains $20 Million To Continue Developing Huntington’s Therapy MTC-1203

News

Mitoconix Bio has secured $20 million in financing to continue developing MTC-1203 as a treatment for mitochondrial impairment in Huntington’s and Parkinson’s diseases. Several pharmaceutical companies and medical-related venture-capital funds ... Read more

June 27, 2017June 27, 2017

Ionis Completes Patient Enrollment in Phase 1/2a Trial of Ionis-HTTRx for Huntington’s Disease

News

Ionis Pharmaceuticals has completed enrollment of the Phase 1/2a study evaluating the safety, tolerability, properties and movement within the body of Ionis-HTTRx in patients with Huntington’s disease (HD). Patients ... Read more

June 22, 2017June 22, 2017

Researchers Identify Variant in MSH3 Gene Related to Huntington’s Progression

News

Researchers have identified a variant in the gene MSH3 that is linked with Huntington’s disease (HD) progression. The study, “Identification of genetic variants associated with Huntington’s disease progression: a ... Read more

June 20, 2017

Inhibiting Enzyme Slows Huntington’s Progression in Mice and Lengthens Their Lives, Study Reports

News

Inhibiting the activity of an enzyme preserved the movement capabilities of mice with Huntington’s, slowed the progression of the disease and extended the animals’ lives, according to a study. ... Read more

June 15, 2017June 15, 2017

Low Pyk2 Protein Levels May Contribute to Memory Deficits in Huntington’s Disease, Study Shows

News

Low levels of a protein called Pyk2 may be associated with the development of Huntington’s disease, according to a new study. Researchers found that normalizing its levels in the ... Read more